Basil Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 23 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.68 M
- Revenue Growth 4.80%
- Profit Growth -5.95%
- Ebitda -10.33%
- Net Worth 9.19%
- Total Assets -13.73%
About Basil Drugs
Basil Drugs Private Limited (BDPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 April 2001 and has a history of 23 years and nine months. Its registered office is in Indore, Madhya Pradesh, India.
The Corporate was formerly known as Basil Drugs Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.68 M.
Rajesh Singh, Mohammad Sheikh, and Tara Kushwaha serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232MP2001PTC014624
-
Company No.
014624
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Apr 2001
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Basil Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Singh
|
Managing Director | 16-Apr-2001 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Mohammad Sheikh
|
Whole-Time Director | 30-Sep-2007 | Current |
|
Tara Kushwaha
|
Whole-Time Director | 16-Apr-2001 | Current |
Financial Performance of Basil Drugs.
Basil Drugs Private Limited, for the financial year ended 2016, experienced modest growth in revenue, with a 4.8% increase. The company also saw a slight decrease in profitability, with a 5.95% decrease in profit. The company's net worth moved up by a moderate rise of 9.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Basil Drugs?
In 2017, Basil Drugs had a promoter holding of 51.09% and a public holding of 48.91%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.68 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.03 Cr
- Icici Bank Limited : 0.02 Cr
- State Bank Of Indore : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Aug 2018 | Others | ₹0.26 M | Open |
| 18 Dec 2015 | Icici Bank Limited | ₹0.23 M | Open |
| 17 Oct 2001 | State Bank Of Indore | ₹0.20 M | Open |
How Many Employees Work at Basil Drugs?
Unlock and access historical data on people associated with Basil Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Basil Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Basil Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
